Valuation: AstraZeneca PLC

Market Cap 258B 226B 214B 195B 364B 24,706B 367B 2,556B 990B 12,622B 968B 947B 40,565B P/E 2026 *
21.2x
P/E 2027 * 18.5x
Enterprise Value 277B 243B 230B 210B 392B 26,594B 395B 2,752B 1,066B 13,586B 1,042B 1,019B 43,664B EV / Sales 2026 *
4.39x
EV / Sales 2027 * 4.02x
Free-Float
96.62%
Yield 2026 *
2.01%
Yield 2027 * 2.13%
1 day+1.09%
1 week+0.95%
Current month+3.12%
1 month+1.58%
3 months-10.17%
6 months-10.71%
Current year-12.76%
1 week 42.7
Extreme 42.7
44.1
1 month 40.87
Extreme 40.87
44.1
Current year 39.97
Extreme 39.97
53.8
1 year 37.3
Extreme 37.3
53.8
3 years 29.05
Extreme 29.05
53.8
5 years 28.2
Extreme 28.2
53.8
10 years 28
Extreme 28
53.8
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%+0.95% - - 258B
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.52%+0.74%+30.13%+48.47% 404.26B
Weighted average by Cap. +0.32%+1.32%+40.43%+68.21%

Financials

2026 *2027 *
Net sales 63.17B 55.43B 52.35B 47.71B 89.3B 6,054B 89.94B 626B 243B 3,093B 237B 232B 9,940B 67.01B 58.8B 55.54B 50.61B 94.74B 6,423B 95.42B 665B 257B 3,281B 252B 246B 10,545B
Net income 12.04B 10.57B 9.98B 9.1B 17.03B 1,154B 17.15B 119B 46.26B 590B 45.22B 44.24B 1,895B 13.77B 12.09B 11.41B 10.4B 19.47B 1,320B 19.61B 137B 52.9B 674B 51.71B 50.59B 2,167B
Net Debt 19.69B 17.28B 16.32B 14.87B 27.84B 1,888B 28.04B 195B 75.65B 964B 73.94B 72.35B 3,099B 11.93B 10.47B 9.89B 9.01B 16.87B 1,144B 16.99B 118B 45.83B 584B 44.8B 43.83B 1,878B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
25/09/26 $43.62 +1.09% 22
24/09/26 $43.15 +1.05% 76
23/09/26 $42.70 -3.17% 42
22/09/26 $44.10 +0.46% 145
21/09/26 $43.90 +1.60% 35
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.19USD
Average target price
211.41USD
Spread / Average Target
+27.21%

Quarterly revenue - Rate of surprise